Literature DB >> 12615442

Immunization with the Chlamydia trachomatis major outer membrane protein, using the outer surface protein A of Borrelia burgdorferi as an adjuvant, can induce protection against a chlamydial genital challenge.

Sukumar Pal1, Catherine J Luke, Alan G Barbour, Ellena M Peterson, Luis M de la Maza.   

Abstract

Two strains of mice C3H/HeN (H-2(k)) and BALB/c (H-2(d)) were immunized with the Chlamydia trachomatis mouse pneumonitis (MoPn) major outer membrane protein (MOMP) using the Borrelia burgdorferi outer surface protein A (OspA) as an adjuvant. As a control, groups of mice were inoculated with ovalbumin instead of MOMP. Female mice were immunized using three different routes: intramuscular (i.m.) plus subcutaneous (s.c.), intranasal (i.n.) and perivaginal and perisacral (p.vag.+p.sac.). Significant humoral and cell mediated immune responses developed particularly in mice inoculated by the i.m.+s.c. routes as determined by the levels of chlamydial specific antibody in the serum and genital secretions and a T-cell proliferative assay. Following immunization the animals were challenged in the genital tract with C. trachomatis MoPn and the course of the infection followed by vaginal cultures. Significant protection against infection was achieved in the C3H/HeN mice inoculated i.m.+s.c. with MOMP+OspA, as shown by the intensity and duration of vaginal cultures, and by the number of mice with positive cultures. On the other hand in BALB/c mice there was only a decrease in the number of animals with positive vaginal cultures. Six weeks after the challenge the mice were mated and the outcome of the pregnancy evaluated. In both the C3H/HeN and the BALB/c mice immunized i.m.+s.c. with MOMP+OspA there was significant protection against infertility as shown by the number of animals with bilateral fertility and number of embryos per uterine horn. In conclusion, immunization using C. trachomatis MOMP, and B. burgdorferi OspA as an adjuvant, can induce significant protection against a chlamydial genital challenge.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12615442     DOI: 10.1016/s0264-410x(02)00680-1

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  14 in total

1.  Protection of mice from a Chlamydia trachomatis vaginal infection using a Salicylidene acylhydrazide, a potential microbicide.

Authors:  Anatoly Slepenkin; Hencelyn Chu; Mikael Elofsson; Pia Keyser; Ellena M Peterson
Journal:  J Infect Dis       Date:  2011-09-20       Impact factor: 5.226

Review 2.  Vaccination against Chlamydia genital infection utilizing the murine C. muridarum model.

Authors:  Christina M Farris; Richard P Morrison
Journal:  Infect Immun       Date:  2010-11-15       Impact factor: 3.441

3.  Broad diversity of host responses of the white-footed mouse Peromyscus leucopus to Borrelia infection and antigens.

Authors:  Vanessa Cook; Alan G Barbour
Journal:  Ticks Tick Borne Dis       Date:  2015-04-28       Impact factor: 3.744

Review 4.  Genital Chlamydia trachomatis: understanding the roles of innate and adaptive immunity in vaccine research.

Authors:  Sam Vasilevsky; Gilbert Greub; Denise Nardelli-Haefliger; David Baud
Journal:  Clin Microbiol Rev       Date:  2014-04       Impact factor: 26.132

Review 5.  Microneedle and mucosal delivery of influenza vaccines.

Authors:  Sang-Moo Kang; Jae-Min Song; Yeu-Chun Kim
Journal:  Expert Rev Vaccines       Date:  2012-05       Impact factor: 5.217

6.  Chlamydia pneumoniae-induced foam cell formation requires MyD88-dependent and -independent signaling and is reciprocally modulated by liver X receptor activation.

Authors:  Shuang Chen; Rosalinda Sorrentino; Kenichi Shimada; Yonca Bulut; Terence M Doherty; Timothy R Crother; Moshe Arditi
Journal:  J Immunol       Date:  2008-11-15       Impact factor: 5.422

7.  A Vibrio cholerae ghost-based subunit vaccine induces cross-protective chlamydial immunity that is enhanced by CTA2B, the nontoxic derivative of cholera toxin.

Authors:  Eno E Ekong; Daniel N Okenu; Jayanti Mania-Pramanik; Qing He; Joseph U Igietseme; Godwin A Ananaba; Deborah Lyn; Carolyn Black; Francis O Eko
Journal:  FEMS Immunol Med Microbiol       Date:  2008-11-18

Review 8.  Chlamydia trachomatis vaccine research through the years.

Authors:  Katelijn Schautteet; Evelien De Clercq; Daisy Vanrompay
Journal:  Infect Dis Obstet Gynecol       Date:  2011-06-26

9.  Chlamydia trachomatis recombinant MOMP encapsulated in PLGA nanoparticles triggers primarily T helper 1 cellular and antibody immune responses in mice: a desirable candidate nanovaccine.

Authors:  Stacie J Fairley; Shree R Singh; Abebayehu N Yilma; Alain B Waffo; Praseetha Subbarayan; Saurabh Dixit; Murtada A Taha; Chino D Cambridge; Vida A Dennis
Journal:  Int J Nanomedicine       Date:  2013-05-30

10.  CCL5 regulation of mucosal chlamydial immunity and infection.

Authors:  Senthilkumar K Sakthivel; Udai P Singh; Shailesh Singh; Dennis D Taub; Joseph U Igietseme; James W Lillard
Journal:  BMC Microbiol       Date:  2008-08-13       Impact factor: 3.605

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.